- $10.73bn
- $10.42bn
- $738.26m
Repligen Corp up on raising FY profit forecast
Brief: Repligen Q3 Adjusted EPS USD 0.43 Vs. IBES Estimate USD 0.33
Repligen Corp expected to post earnings of 33 cents a share - Earnings Preview
Repligen Corp expected to post earnings of 33 cents a share - Earnings Preview
Brief: Repligen Corp -Consolidated Financial Statements For Quarter Ended March 31, 2023 Through June 30, For Year Ended Dec 31, 2023 Require Restatement
Repligen in bid for reagent vendor Maravai, sources say
Repligen falls after report company bids to acquire Maravai LifeSciences
Repligen in bid for reagent vendor Maravai, sources say
Brief: Repligen Q2 Adjusted EPS USD 0.33 Vs. IBES Estimate USD 0.33
Brief: Repligen Announces Agreement To Acquire Chromatography Innovator Tantti
Repligen Corp expected to post earnings of 33 cents a share - Earnings Preview
Brief: Repligen Corp Say Unauthorized Third Party Had Accessed Certain Files On Co's Information Systems
U.S. RESEARCH ROUNDUP-Carmax, Eli Lilly, Microstrategy
U.S. STOCKS ON THE MOVE-ACI Worldwide, enCore Energy, Adobe
U.S. STOCKS ON THE MOVE-Williams-Sonoma, ACI Worldwide, enCore Energy
Repligen's longtime CEO to step down; shares drop
Repligen falls on CEO transition
Brief: Repligen Announces CEO Transition Plan
Repligen Corp reports results for the quarter ended in March - Earnings Summary